Tenet Healthcare Corporation, together with its subsidiaries, primarily operates acute care hospitals and related healthcare facilities. The company operates through three segments: Hospital Operations and Other, Ambulatory Care, and Conifer. Its general hospitals offer acute care services, operating and recovery rooms, radiology services, respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive, critical, and coronary care units; physical therapy, orthopedic, oncology, and outpatient services; tertiary care services, including open-heart surgery, neonatal intensive care, and neurosciences; quaternary care services for heart, liver, kidney, and bone marrow transplants; quaternary pediatric and burn services; gamma-knife brain surgery; and cyberknife radiation therapy for tumors and lesions in the brain, lung, neck, and spine. In addition, it offers clinical research programs related to cardiovascular and pulmonary diseases, musculoskeletal disorders, neurological disorders, genitourinary diseases, and various cancers, as well as drug and medical device studies. Further, the company operates freestanding ambulatory surgery and imaging centers, short-stay surgical facilities, and Aspen's hospitals and clinics. Additionally, it offers operational management for patient access, accounts receivable management, health information management, revenue integrity, and patient financial services; communications and engagement solutions; and clinical integration, financial risk management, and population health management services. As of December 31, 2015, the company operated 86 hospitals, 20 short-stay surgical hospitals, and approximately 475 outpatient centers; and 9 private hospitals and clinics, as well as 249 ambulatory surgery, 20 imaging, and 35 urgent care centers in the United Kingdom. Tenet Healthcare Corporation was founded in 1967 and is headquartered in Dallas, Texas.
Tenet Healthcare ($THC) is moving sharply lower in pre-market trading after the hospital operator’s fourth quarter results missed estimates. The company also forecast weaker than expected full year earnings.
This was a leak two weeks ago. Now we know why it sold off 15%. This is way way over done. But short sellers have control. 3-day buy.
